cyrilzakka/clinical-trials huggingface dataset:
Early Rehospitalization of Persons Aged 75 Years or Older Admitted to a Geriatric Post-emergency Unit.

The older population is increasing, and one of the challenges is to prevent functional disability. Longer hospital stays are a recognized factor in dependency. Older subjects may present multiple complications, and therefore be frequently readmitted to hospital. Readmission to hospital is a costly and iatrogenic event in terms of independence, and must therefore be limited. The most vulnerable older patients therefore require specific care to avoid these iatrogenic complications, and various innovative structures have been developed, such as mobile geriatric teams, carrying out assessments in emergency departments, or geriatric post-emergency units with a shorter length of stay to reduce the iatrogenic impact of hospitalization.In November 2022, a temporary hospitalisation unit based on this model was opened at the CHU d'Angers with 11 beds. The aim of this study is to estimate the rate of early rehospitalisation (\< 30 days) between December 2022 and September 2023, and the factors associated with it. Once identified, these factors will allow us to further select patient profiles that are suitable for care in these very short stay units.


Eligibility Criteria:
Inclusion Criteria:

- Patient admitted to the temporary geriatric hospitalization unit between December 1, 2022 and September 30, 2023

Exclusion Criteria:

* Patients moved to another medical, surgical or obstetrics department of the Angers University Hospital during their stay.
* Death during stay.
* Patient assigned to a unit other than the temporary geriatric hospitalization unit.
* Patient already hospitalized in the unit during the recruitment campaign.
* Opposition to data use
the New Geneswell BCT in Vitro Diagnosis of Breast Cancer Prognosis

Geneswell BCT is a precise and qualitative in vitro diagnostic test. The expression of 9 genes was obtained from the formalin fixed paraffin embedded block (FFPE) of breast cancer tissue samples by RT-qPCR, and the patients were divided into high-risk group and low-risk group.

This test provides prognostic information to assess the risk of recurrence. The BCT score calculated by geneswell BCT was associated with the risk of recurrence. The higher the BCT score, the more likely it is to relapse, and vice versa.


Eligibility Criteria:
Inclusion Criteria:

* The patients were diagnosed with invasive breast cancer with positive hormone receptor (including positive estrogen receptor or progesterone receptor) and negative human epidermal growth factor receptor 2 (HER2)
* Axillary lymph node assessment : pN0 or PN1
* Women aged 18 and over
* Patients without chemotherapy after operation

Exclusion Criteria:

* Patients with negative hormone receptor （both estrogen and progesterone receptor are negative）
* Human epidermal growth factor receptor 2 （HER2） positive
* Pathological nodule evaluation: pN2 or pN3
* Male patients
* Patients receiving chemotherapy after surgery
Evaluation of the Benefits of Sublingual AIT (PRACTIS)

The objective of the study was to evaluate in routine practice the benefits of sublingual allergen immunotherapy (SLIT) for allergic patients with allergic rhinitis (AR), with or without asthma, according to various methods of use (treatment regimen: formulation type, dose, duration, initiation) and type of allergen (grass pollen, tree pollen, herbaceous pollen, house dust mites, animal dander, moulds and poly-reactive types).

The treatment considered was any SLIT (tablet or liquid forms) accepted by the patient and the parent(s) in the case of minor patients. The treatment was taken as prescribed by the observing physician.

The expected benefits for patients after approximately 6 and 12 months after initiation of SLIT included:

* Decreased intensity of symptoms
* Decreased discomfort
* Decreased consumption of symptomatic treatments or associated treatments (especially in asthmatic patients)
* Improved quality of life
* Reduced absenteeism from school or work
* Beneficial impact on leisure activities.

Eligibility Criteria:
Inclusion Criteria:

* Patients aged 5 years or older
* Patients with a respiratory allergy with significant clinical symptoms and whose diagnosis was confirmed by a positive skin prick-test and/or the presence of specific IgE antibodies to one or more allergens implicated in the symptoms
* Patients eligible for AIT (patients who had been treated with AIT in the 3 years prior to the inclusion visit could be included if starting a new form and/or type of AIT)
* Patients previously treated with a pharmacological AR treatment in the month before the inclusion visit or during the previous pollen season, and requiring the initiation of AIT
* Patients (and/or their parents or legal representatives as appropriate) agreeing to take part in the study after having been informed orally and in writing by the observing physician.

Exclusion Criteria:

* Patient with a hypersensitivity (allergy) to any of the excipients in the selected AIT
* Patients taking beta-blockers (including local treatments, e.g. eye drops)
* If asthmatic patient:
* Patients with uncontrolled (unstable) or severe asthma (in adults this was defined as daily symptoms and FEV1 \<70% of the theoretical value after appropriate drug treatment, and in children and adolescents by FEV1 \<80% of the theoretical value after appropriate drug treatment)
* Patients who have had a severe asthma exacerbation in the last three months
* Asthmatic patient with unresolved acute infection of the airways.
Tryptophan and Behavior Therapy for Cocaine Abuse - 1

The purpose of this study is to assess the efficacy of tryptophan vs. placebo, and voucher payments vs. a control condition, in the treatment of cocaine dependence.

This clinical trial uses a 2 by 2 design to compare tryptophan to placebo, and voucher incentives vs. a control condition, in the outpatient treatment of cocaine dependence- using a relapse prevention model of treatment intervention.

Eligibility Criteria:
Inclusion Criteria:

* Cocaine dependent

Exclusion Criteria:

* Physically dependent on drugs of abuse other than cocaine
* Significant medical or psychiatric illness (besides substance abuse disorder)
* Pregnant
Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy

Rationale: Dual antiplatelet therapy, consisting of aspirin and a P2Y12-inhibitor, reduces the risk of stent thrombosis, myocardial infarction and stroke after coronary stent implantation. Inevitably, it is also associated with a higher risk of (major) bleeding. Given the advances in stent properties, stenting implantation technique and pharmacology, it may be possible to treat patients with a single antiplatelet strategy using a potent P2Y12-inhibitor such as prasugrel or ticagrelor.

Objective: This study will serve as a pilot to investigate the feasibility and safety of a single antiplatelet strategy with prasugrel or ticagrelor prior to, during and after stent implantation in 75 patients with non-ST segment elevation acute coronary syndrome.

Study design: Single-center, single arm pilot study with a stopping rule based on the occurrence of definite stent thrombosis.

Study population: Patients presenting with non-ST segment elevation acute coronary syndrome and (a) 'de novo' lesion(s) treated with new generation drug-eluting stent(s) with adequate reduction of platelet reactivity according to platelet function testing with VerifyNow and optimal stenting result adjudicated by optical coherence tomography or coronary angiography.

Intervention: Once daily 10 mg prasugrel or twice daily 90 mg ticagrelor for 12 months preceded by a loading dose of 60 mg prasugrel or 180 mg ticagrelor at least 2 hours prior to percutaneous coronary intervention without concurrent aspirin therapy.

Main study endpoint: The primary ischemic endpoints is the composite of all-cause mortality, myocardial infarction, Academic Research Consortium defined stent thrombosis and ischemic stroke at 6 months after percutaneous coronary intervention. The primary bleeding outcome is major or minor bleeding defined as Bleeding Academic Research Consortium type 2, 3 or 5 bleeding at 6 months after percutaneous coronary intervention.


Eligibility Criteria:
Inclusion Criteria:

* NSTE-ACS diagnosis
* 'De novo' coronary lesion(s) eligible for PCI
* Written informed consent

Exclusion Criteria:

* Known allergy or contraindication for prasugrel and ticagrelor use.
* Concurrent use of oral anticoagulants
* Overwriting indication for DAPT
* Planned surgical intervention within 12 months of planned revascularization
* PCI of left main disease, chronic total occlusion, bifurcation lesion requiring two-stent treatment, saphenous or arterial graft lesion, severely calcified lesions
* Recent or ongoing strong CYP3A4 inhibitor or inducer therapy
* Recent or ongoing therapy with CYP4A4-substrates with a narrow therapeutic index
* Pregnant or breastfeeding women at time of enrolment
* Participation in another trial with an investigational drug or device (i.e. stent)
Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients

The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare with placebo.

The efficacy and safety will be compared between Chiglitazar and placebo after treatment of 24 weeks. The long term efficacy and safety of Chiglitazar will be evaluated after 52 weeks treatment.

Eligibility Criteria:
Inclusion Criteria:

1. Meet the WHO Diagnostic Criteria for Type 2 Diabetes (published on 1999);
2. HbA1c≥ 7.5% and ≤ 10.0% after control of diet and exercises;
3. Male and female,age between 18 and 70 years;
4. BMI between 18.5-35kg/m2;
5. Willing to be assigned to any treatment arm and sign inform consent.

Exclusion Criteria:

1. Type 1 diabetes;
2. Treated by oral or injective antidiabetic drug before screening, including insulin and herb;
3. Fasting plasma glucose \> 13.3 mmol/L (240 mg/dL);
4. Resistant hypertension \[blood pressure above the goal despite adherence to at least 3 optimally dosed antihypertensive medications (including diuretic) of different classes,or blood pressure is controlled to below the goal by at least 4 different classes of drugs\];
5. Plasma triglyceride \> 500 mg/dL (5.65 mmol/L);
6. Is treating by fibrates;
7. History of diabetic ketoacidosis,diabetic hyperglycemic hyperosmolar syndrome,lactic acidosis, diabetic hypoglycemia; or is currently combined with retinopathy, diabetic nephropathy and diabetic neuropathy;
8. Had transient ischemic attack,cerebrovascular accident or unstable angina in the past 6 months;
9. History of myocardial infarction or had conducted coronary angioplasty or coronary artery bypass graft surgery;
10. Heart failure (NYHA classification Stage III or IV), or left ventricular hypertrophy indicated by ECG;
11. Hepatic diseases such as hepatocirrhosis, active hepatitis,aspartate aminotransferase or alanine aminotransferase \> 2.5 fold of the upper limit of the normal range;
12. Kidney diseases or serum creatinine exceed the normal range: male \> 133 μmol/L or female \>108 μmol/L;
13. Had malignancy in the past 5 years, not including basal cell carcinoma;
14. Had or is currently receiving treatment that can alter blood glucose metabolism, including but not limited to diuretic,hormone (corticotropin or steroids),beta blockers;
15. Have the diseases that can alter blood glucose metabolism, including but not limited to active hepatitis, hyperthyroidism,or adrenal tumors;
16. Edema with unknown reason;
17. Alcohol or drug addiction;
18. Had participated other drugs' clinical trials in the 3 months before screening;
19. Pregnant or lactic women; or women of childbearing age who are not able to or is not willing to conduct contraception;
20. Any condition that make investigator consider the subject is not suitable to participate the trial.
Wound Infiltration With Local Anesthetic Agent for Laparoscopic Appendectomy in Adult

Acute appendicitis is one of the most common acute abdomens that need surgical intervention. Laparoscopic surgery much decreases postoperative pain of wound, however, pain remains an important determinant of recovery after surgery. Intraoperative local anesthetic agent infiltrated locally into surgical wound to relieve postoperative pain is a feasible and safe method suggested in some literature. However, there is no routine use of this method in clinical practice because its benefit is still unknown. Besides, very few evidence could be found in literature review. To date, there is still no double blinded, prospective, randomized control trial addressing in evaluation of its interest. In this study, the investigators aim at investigating the benefit of wound infiltration with local anesthetic agent (bupivacaine) for laparoscopic appendectomy in adult. The study design is a double blind, prospective, randomized control trial with a 1:1 allocation ratio. Fifty adult patients with appendicitis will be included. The control group undergo laparoscopic appendectomy without wound infiltration with local anesthetic agent, the intervention group undergo laparoscopic appendectomy with wound infiltration with local anesthetic agent intraoperatively. The clinical characteristics, outcomes, and patient's satisfaction will be recorded and analyzed. The investigators hope this study can provide a high level evidence in pain management of patient undergo laparoscopic surgery.


Eligibility Criteria:
Including criteria:

1. Clinical diagnosis of appendicitis and undergo laparoscopic appendectomy
2. Age more than 20 years
3. Well comprehensive in speaking Chinese

Exclusion criteria:

1. Age no more than 20 years
2. Pregnancy
3. Can not cooperate with evaluation
4. Convert to open surgical method, resect more organs than appendix
5. Using patient control analgesia
6. Allergy to local anesthetic agent
A Clinical Trial to Compare and Evaluate the Pharmacokinetic Characteristics and the Safety of Fimasartan in Hepatic Impairment Patients and Healthy Volunteers

To compare and evaluate the pharmacokinetic characteristics and the safety of fimasartan in hepatic impairment patients and healthy volunteers


Eligibility Criteria:
Inclusion Criteria:

\<Hepatic impairment patient\>

* age: 20 - 64 years
* sex: male
* Child-Pugh score A or Child-Pugh score B
* body weight: greater than 55 kg
* written informed consent

\<Healthy volunteer\>

* age: 20 - 64 years
* sex: male
* body weight: greater than 55 kg
* written informed consent

Exclusion Criteria:

\<Hepatic impairment patient\>

* portosystemic shunt surgery
* Child-Pugh score C
* creatinine clearance \< 80mL/min
* ascites

\<Healthy volunteer\>

* AST(SGOT), ALT(SGPT) \> 1.5 times of Upper Normal Range
* Total bilirubin \> 1.5 times of Upper Normal Range
* positive drug or alcohol screening
Patient Sleep Position Questionnaire

You are being asked to participate in this study because we would like to know if sleeping may affect eye pressure.

Completion of the questionnaire is done solely for research purposes and is not part of your routine care.

Approximate duration- Up to 10 minutes to complete the questionnaire.

Eligibility Criteria:
Inclusion Criteria:

* Glaucoma
* Age-matched controls
* Adults

Exclusion Criteria:

* Medical students
* Children
Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women

The purpose of this study is to assess clinical outcomes after Letrozole treatment according to the estrogen receptor expression in postmenopausal women with hormone receptor positive breast cancer.

This study aimed at evaluating following:

1. Validity Assessment:

   1. Primary End Point: To evaluate 5-year diseae free survival rate after Letrozole treatment according to the estrogen receptor expression in postmenopausal women
   2. Secondary End Point: To evaluate overall survival rate(OS) and Time to distance recurrence(TTDR) after Hormonal therapy in postmenopausal women with hormone receptor positive breast cancer
2. Safety Assessment: To evaluate all adverse events including serious adverse events after Letrozole treatment.

Eligibility Criteria:
Inclusion Criteria:

1. Patients with estrogen receptor(+) and/or progesterone receptor(+)
2. Postmenopausal state was defined the following conditions, at least one of a, b

   1. Serum FSH ≥ 30 mIU/mL and Amenorrhea ≥ 1 year for below 55 years, over than 55 years
   2. Bilateral oophorectomy
3. Patients have undergone surgery of the breast cancer within 12 weeks and terminated chemotherapy after surgery within 4 weeks.
4. WHO(ECOG) performance status 0-2
5. Adequate haematological function, renal function, hepatic function.
6. No evidence of metastasis.

Exclusion Criteria:

1. Metachronous bilateral breast cancer.
2. Metastatic breast cancer (stage IV)
3. Other hormone therapy and Hormonal replacement therapy given within the previous 4 weeks, except for Estring, Vagifem, Estrogen Cream.
4. Patients with Child-Pugh grade C, serum creatinine\>2xUNL
5. Patients with gastrectomy, small bowel resection, malabsorption syndrome and dysphagia.
Emergency Department Management of Femur Fractures

Comparison of emergency department management of patients presenting with isolated hip fracture: comparison of methods used in pain management, monitoring, and treatment; comparison of hospitalization durations; comparison of mortality

Patient demographics, mechanism of injury, femur fracture classification, associated treatments, pre-procedural pain scoring, post-procedural pain scoring, orthopedic consultation, and patient outcomes (discharge, admission to ward or ICU, mortality) will be recorded on the data form.

For acute pain management, the timing of treatment administration, effectiveness of the applied method based on pre- and post-procedural pain scoring systems will be assessed. Post-procedural pain scores will be collected at 30, 60, and 120 minutes.

Long-term complications as a result of hospitalization following emergency department follow-ups will include monitoring on days 7 and 21 for mortality and morbidity.

The patients will be analyzed in 5 groups based on the treatments administered in the emergency department.

1. IV Opioid
2. IV NSAID
3. IV acetaminophen
4. Femoral nerve block
5. PENG block The researcher will not interfere with the treatment decision made by the responsible physician or the treatment process

Eligibility Criteria:
Inclusion Criteria:

Patients over the age of 18 years

Exclusion Criteria:

Forensic cases Patients who do not have follow-up in our healthcare system or cannot be followed up Patients with allergies to opioids or local anesthetics Patients with suspected neuropathy among defined complications of diabetes mellitus Patients requiring treatment for ≥2 different types of fractures upon emergency department admission
A Study to Assess the Safety and Efficacy of ADVAGRAF (Tacrolimus Modified Release Formulation) in Kidney Transplant Patients Who Were Treated With PROGRAF

The purpose of this study is to evaluate the efficacy of tacrolimus modified release formulation Advagraf® after conversion from Prograf® in stable kidney transplant patients.


Eligibility Criteria:
Inclusion Criteria:

1. Patients received a kidney transplant at least 12 months ago prior to enrollment.
2. Patients have taken unchanged dosage of Prograf® and remained stable serum level of tacrolimus at least for 12 weeks prior to enrollment.
3. Patients have kept in unchanged immunosuppressive therapy (combination therapy) at least for 12 weeks prior to enrollment.
4. Female patients of childbearing potential must have a negative urine or serum pregnancy test prior to enrollment, and agreed to the deliberate prevention of conception during the trial.
5. Patients are considered clinically stable by observer's judgment.
6. Patients must understand the purpose and risk of participating the trial and signed on the written consent.

Exclusion Criteria:

1. Patients have previously received an organ transplant other than a kidney.
2. Patients have had acute transplant rejection within 12 weeks, or acute transplant rejection requiring antilymphocyte therapy within 24 weeks prior to enrollment.
3. Patients newly diagnosed malignant tumors after organ transplant but the patients treated completely with basal or squamous cell carcinoma of the skin are excepted.
4. Patients have a known hypersensitivity to Prograf® or tacrolimus.
5. Patients whose medical condition are able to interfere with the study objectives.
6. Patients who are at the risk of drug abuse or mental disorders or communicate difficulties with the observer.
7. Patients have been participated in another clinical trial, or treated with drugs of clinical trial within 28 days prior to enrollment.
8. Patients have been taken prohibited combination agents within 28 days prior to enrollment.
9. Patients are pregnant or lactating.
10. Patient are HIV-positive.
11. Patients are not able to keep the scheduled visit.
12. Patients whose GFR (MDRD) is in the level of \<30 mL/min.
13. Patients who are at the condition of 'Creeping creatinine (defined by 20% increase within 6 months prior to enrollment)
14. Patients whose SGPT/AST and/or SGOT/ALT levels have been elevated greater than 2 times the upper value of the normal range.
15. Patients have FSGS or MPGN Type II as underlying diseases.
16. Patients are with cirrhosis
Conventional Bronchoscope With BAL vs. Thin Bronchoscope With BW to Diagnose Pulmonary TB

This study aims to compare the diagnostic yield of bronchoalveolar lavage (BAL) using a thick conventional bronchoscope and bronchial washing (BW) using a thin bronchoscope in the diagnosis of pulmonary tuberculosis.

In patients with suspected pulmonary tuberculosis (TB), confirm the presence of TB bacilli through sputum testing is essential for diagnosis. However, the sensitivity of sputum specimens is suboptimal, and some patients may be unable to produce sputum. In such situations, it is traditionally known that obtaining samples through bronchoscopy increases the diagnostic yield of pulmonary TB. Typically, the method of using a thick, conventional bronchoscope to perform bronchial washing (BW) or bronchoalveolar lavage (BAL) is commonly employed. However, a drawback of the conventional bronchoscope is its inability to reach close to peripheral pulmonary TB lesions due to its larger diameter.

Recent studies have reported an increased diagnostic yield for pulmonary TB when using a thin bronchoscope for BW compared to using a thick, conventional bronchoscope for BW. However, a direct comparison with the method of performing BAL (BAL may have a higher diagnostic yield compared to BW) using a conventional bronchoscope has not been conducted. This study aims to prospectively compare the diagnostic yield for pulmonary TB between BAL using a conventional bronchoscope and BW using a thin bronchoscope.

Eligibility Criteria:
Inclusion Criteria:

* participants age \> 17 years with suspected pulmonary TB
* possible active pulmonary TB evident on chest radiography or CT scan
* negative AFB smear results (using two consecutive self-expectorated sputum)
* negative TB-PCR results (using one self-expectorated sputum)
* inability to produce self-expectorated sputum

Exclusion Criteria:

* a request for empirical TB treatment rather than bronchoscopy
* suspect pulmonary TB lesions that are difficult to target for BAL or BW (e.g., multiple discrete tiny nodules)
* contra-indication of bronchoscopy (e.g., bleeding tendency, hypoxemia requiring oxygen, or uncontrolled cardio/cerebrovascular disease)